Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Eastern Cooperative Oncology Group.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Southwest Oncology Group
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00005034
First received: April 6, 2000
Last updated: April 2, 2013
Last verified: November 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | No date given |
Publications:
Falkson CI, Lawson DH, Ibrahim J, et al.: A randomised, placebo-controlled phase III trial of yeast derived GM-CSF vs. peptide vaccination vs. GM-CSF plus peptide vaccination vs. placebo in pts with 'no evidence of disease' after complete surgical resection of 'locally advanced' and / or stage IV melanoma. An Eastern Cooperative group trial . [Abstract] 4th International Conference on the Adjuvant Therapy of Malignant Melanoma, 15th-16th March 2002, London, UK A-I-03, 2002.